Curcumin attenuates the effects of insulin on stimulating hepatic stellate cell activation by interrupting insulin signaling and attenuating oxidative stress

Laboratory Investigation

Volumn 89, Issue 12, 2009, Pages 1397-1409

  Lin, Jianguo ^a   Zheng, Shizhong ^a   Chen, Anping ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatic fibrosis; Hepatic stellate cell; Hyperinsulinemia; Insulin; Non alcoholic fatty liver disease; Phytochemical

Indexed keywords

COLLAGEN TYPE 1; CURCUMIN; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; INSULIN; INSULIN RECEPTOR;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; EFFECTOR CELL; GENE EXPRESSION; GENE REPRESSION; GLUTATHIONE METABOLISM; HYPERINSULINEMIA; LIVER CELL; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR GENE; SIGNAL TRANSDUCTION; STELLATE CELL;

ANIMALS; CELLS, CULTURED; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; HEPATIC STELLATE CELLS; HYPERINSULINISM; INSULIN; INSULIN ANTAGONISTS; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 70549101361     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.115     Document Type: Article

References (54)

1. Maiese K, Morhan SD, Chong ZZ. Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res 2007;4:63-71. (Pubitemid 46280293)
2. Leclercq IA, Da Silva Morais A, Schroyen B, et al. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007;47:142-156.
3. Dandona P, Aljada A, Chaudhuri A, et al. A novel view of metabolic syndrome. Metab Syndr Relat Disord 2004;2:2-8.
4. Khamzina L, Gruppuso PA, Wands JR. Insulin signaling through insulin receptor substrate 1 and 2 in normal liver development. Gastroenterology 2003;125:572-585.
5. Tsochatzis E, Papatheodoridis GV, Manesis EK, et al. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008;27:80-89.
6. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40(Suppl 1):S5-S10.
7. Friedman SL Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-1669.
8. Kisseleva T, Brenner DA. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 2006;21(Suppl 3):S84-S87.
9. Hendriks HF, Brekelmans PJ, Buytenhek R, et al. Liver parenchymal cells differ from the fat-storing cells in their lipid composition. Lipids 1987;22:266-273.
10. Yamada M, Blaner WS, Soprano DR, et al. Biochemical characteristics of isolated rat liver stellate cells. Hepatology 1987;7:1224-1229.
11. Friedman SL, Rockey DC, McGuire RF, et al. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology 1992;15: 234-243.
12. Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999;29:1743-1751.
13. Di Sario A, Candelaresi C, Omenetti A, et al. Vitamin E in chronic liver diseases and liver fibrosis. Vitam Horm 2007;76:551-573.
14. Das KS, Balakrishnan V, Mukherjee S, et al. Evaluation of blood oxidative stress-related parameters in alcoholic liver disease and nonalcoholic fatty liver disease. Scand J Clin Lab Invest 2008;68:323-334.
15. Halliwell B. Drug antioxidant effects. A basis for drug selection? Drugs 1991;42:569-605.
16. Svegliati-Baroni G, De Minicis S, Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int 2008;28:1052-1064.
17. Sreejayan N, Rao MN. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 1994;46:1013-1016.
18. O'Connell MA, Rushworth SA. Curcumin: potential for hepatic fibrosis therapy? Br J Pharmacol 2008;153:403-405.
19. Fu Y, Zheng S, Lin J, et al. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 2008;73:399-409.
20. Xu J, Fu Y, Chen A. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol 2003;285:G20-G30.
21. Zheng S, Chen A. Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J 2004;384: 149-157.
22. Zheng S, Chen A. Curcumin suppresses the expression of extracellular matrix genes in activated hepatic stellate cells by inhibiting gene expression of connective tissue growth factor. Am J Physiol Gastrointest Liver Physiol 2006;290:G883-G893.
23. Chen A, Zhang L. The antioxidant (-)-epigallocatechin-3-gallate inhibits rat hepatic stellate cell proliferation in vitro by blocking the tyrosine phosphorylation and reducing the gene expression of platelet-derived growth factor-beta receptor. J Biol Chem 2003;278:23381-23389.
24. Schmittgen TD, Zakrajsek BA, Mills AG, et al. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 2000;285:194-204.
25. Lin J, Chen A. Activation of peroxisome proliferator-activated receptor-gamma by curcumin blocks the signaling pathways for PDGF and EGF in hepatic stellate cells. Lab Invest 2008;88:529-540.
26. Zheng S, Yumei F, Chen A. De novo synthesis of glutathione is a prerequisite for curcumin to inhibit hepatic stellate cell (HSC) activation. Free Radic Biol Med 2007;43:444-453.
27. Fraser JA, Kansagra P, Kotecki C, et al. The modifier subunit of Drosophila glutamate-cysteine ligase regulates catalytic activity by covalent and noncovalent interactions and influences glutathione homeostasis in vivo. J Biol Chem 2003;278:46369-46377.
28. Zhou Y, Zheng S, Lin J, et al. The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPARgamma in rat activated hepatic stellate cell in vitro. Lab Invest 2007;87:488-498.
29. De Minicis S, Brenner DA. Oxidative stress in alcoholic liver disease: role of NADPH oxidase complex. J Gastroenterol Hepatol 2008;23(Suppl 1):S98-S103.
30. Wu G, Fang YZ, Yang S, et al. Glutathione metabolism and its implications for health. J Nutr 2004;134:489-492.
31. Fridovich I. The biology of oxygen radicals. Science 1978;201: 875-880.
32. Jones DP. Redox potential of GSH/GSSG couple: assay and biological significance. Methods Enzymol 2002;348:93-112.
33. Cotgreave IA. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol 1997;38:205-227.
34. Anderson ME, Luo JL. Glutathione therapy: from prodrugs to genes. Semin Liver Dis 1998;18:415-424.
35. Zheng S, Chen A. Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2007;292:G113-G123.
36. Mueller AS, Bosse AC, Most E, et al. Regulation of the insulin antagonistic protein tyrosine phosphatase 1B by dietary Se studied in growing rats. J Nutr Biochem 2008;20:235-247.
37. Gerthoffer WT. Signal-transduction pathways that regulate visceral smooth muscle function. III. Coupling of muscarinic receptors to signaling kinases and effector proteins in gastrointestinal smooth muscles. Am J Physiol Gastrointest Liver Physiol 2005;288: G849-G853.
38. Nilsson BO, Gomez MF, Sward K, et al. Regulation of Ca2+ channel and phosphatase activities by polyamines in intestinal and vascular smooth muscle-implications for cellular growth and contractility. Acta Physiol Scand 2002;176:33-41.
39. Tani E, Matsumoto T. Continuous elevation of intracellular Ca2+ is essential for the development of cerebral vasospasm. Curr Vasc Pharmacol 2004;2:13-21.
40. Syng-Ai C, Kumari AL, Khar A. Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Mol Cancer Ther 2004;3:1101-1108.
41. Peschel D, Koerting R, Nass N. Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J Nutr Biochem 2007;18:113-119.
42. Kang Q, Chen A. Curcumin suppresses gene expression of low-density lipoprotein receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cell. Brit J Pharmacol 2009;157:1354-1367.
43. Murugan P, Pari L, Rao CA. Effect of tetrahydrocurcumin on insulin receptor status in type 2 diabetic rats: studies on insulin binding to erythrocytes. J Biosci 2008;33:63-72.
44. Seo KI, Choi MS, Jung UJ, et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 2008;52:995-1004.
45. Suryanarayana P, Saraswat M, Mrudula T, et al. Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest Ophthalmol Vis Sci 2005;46:2092-2099.
46. Pari L, Murugan P. Effect of tetrahydrocurcumin on blood glucose, plasma insulin and hepatic key enzymes in streptozotocin induced diabetic rats. J Basic Clin Physiol Pharmacol 2005;16:257-274.
47. Sharma S, Kulkarni SK, Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006;33:940-945.
48. Galicia-Moreno M, Rodriguez-Rivera A, Reyes-Gordillo K, et al. N-acetylcysteine prevents carbon tetrachloride-induced liver cirrhosis: role of liver transforming growth factor-beta and oxidative stress. Eur J Gastroenterol Hepatol 2009;21:908-914.
49. Pereira-Filho G, Ferreira C, Schwengber A, et al. Role of N-acetylcysteine on fibrosis and oxidative stress in cirrhotic rats. Arq Gastroenterol 2008;45:156-162.
50. Tahan G, Tarcin O, Tahan V, et al. The effects of N-acetylcysteine on bile duct ligation-induced liver fibrosis in rats. Dig Dis Sci 2007;52:3348-3354.
51. Garcea G, Jones DJ, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004;90:1011-1015.
52. Motterlini R, Foresti R, Bassi R, et al. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 2000;28:1303-1312.
53. Shakibaei M, John T, Schulze-Tanzil G, et al. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochem Pharmacol 2007;73:1434-1445.
54. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001;7:1894-1900.